Asset Details
Do you wish to reserve the book?
Anti- p -benzoquinone antibody level as a prospective biomarker to identify smokers at risk for COPD
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Anti- p -benzoquinone antibody level as a prospective biomarker to identify smokers at risk for COPD
Do you wish to request the book?
Anti- p -benzoquinone antibody level as a prospective biomarker to identify smokers at risk for COPD
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Anti- p -benzoquinone antibody level as a prospective biomarker to identify smokers at risk for COPD
2017
Overview
Identification of smokers having predisposition to COPD is important for early intervention to reduce the huge global burden of the disease. Using a guinea pig model, we have shown that
-benzoquinone (
-BQ) derived from cigarette smoke (CS) in the lung is a causative factor for CS-induced emphysema.
-BQ is also derived from CS in smokers and it elicits the production of anti-
-BQ antibody in humans. We therefore hypothesized that anti-
-BQ antibody might have a protective role against COPD and could be used as a predictive biomarker for COPD in smokers. The objective of this study was to compare the serum anti-
-BQ antibody level between smokers with and without COPD for the evaluation of the hypothesis.
Serum anti-
-BQ antibody concentrations of current male smokers with (n=227) or without (n=308) COPD were measured by an indirect enzyme-linked immunoabsorbent assay (ELISA) developed in our laboratory. COPD was diagnosed by spirometry according to Global Initiative for Chronic Obstructive Lung Disease (GOLD) guidelines.
A significant difference was observed in the serum anti-
-BQ antibody level between smokers with and without COPD (Mann-Whitney
-test =4,632.5,
=0.000). Receiver operating characteristic (ROC) curve analysis indicated that the ELISA had significant precision (area under the curve [AUC] =0.934, 95% confidence interval [CI]: 0.913-0.935) for identifying smokers with COPD from their low antibody level. The antibody cutoff value of 29.4 mg/dL was constructed from the ROC coordinates to estimate the risk for COPD in smokers. While 90.3% of smokers with COPD had a low antibody value (≤29.4 mg/dL), the majority (86.4%) of smokers without COPD had a high antibody value (≤29.4 mg/dL); 13.6% of current smokers without COPD having an antibody level below this cutoff value (odds ratio [OR] =59.3, 95% CI: 34.15-101.99) were considered to be at risk for COPD.
Our results indicate that serum anti-
-BQ antibody level may be used as a biomarker to identify asymptomatic smokers at risk for COPD for early intervention of the disease.
Publisher
Dove Medical Press Limited,Dove Medical Press Ltd,Dove Medical Press
Subject
/ Analysis
/ anti-p-benzoquinone antibody
/ Antigens
/ Benzoquinones - adverse effects
/ Chronic obstructive lung disease
/ Chronic obstructive pulmonary disease
/ COPD
/ enzyme- linked immunosorbent assay (ELISA)
/ Enzyme-Linked Immunosorbent Assay
/ Humans
/ Male
/ Pulmonary Disease, Chronic Obstructive - blood
/ Pulmonary Disease, Chronic Obstructive - diagnosis
/ Pulmonary Disease, Chronic Obstructive - immunology
/ Pulmonary Disease, Chronic Obstructive - physiopathology
/ Smokers
/ Smoking
